Related by context. All words. (Click for frequent words.) 64 nonrandomized 60 noninferiority 60 subanalysis 59 subgroup analyzes 59 meta analysis 58 multicentre randomized 57 randomized multicenter 57 non inferiority 57 randomized controlled 56 randomized placebo controlled 56 placebo controlled 56 RE LY 56 HCV SPRINT 56 placebo controlled trials 56 substudy 56 prospective randomized controlled 56 prospective randomized 55 multicentre 55 MERLIN TIMI 55 prespecified 55 ALLHAT 55 phase IIIb 55 ONTARGET 55 prospectively defined 55 placebo controlled studies 55 blind randomized 54 nab paclitaxel 54 randomized 54 variance ANOVA 54 EURIDIS 54 randomized clinical 54 RE LY ® 54 multicenter randomized 54 viral kinetic 54 primary endpoint 54 meta analyzes 54 AIM HIGH 54 randomized clinical trials 54 trials RCTs 54 achieved statistical significance 54 Randomised 54 randomized trials 54 RCTs 54 placebo controlled randomized 54 active comparator 53 prospective multicenter 53 randomized controlled trials 53 TRITON TIMI 53 ExTRACT TIMI 53 primary efficacy endpoint 53 Subgroup analyzes 53 ANOVA 53 composite endpoint 53 prospective randomized multicenter 53 placebo controlled clinical 53 peginterferon alfa 2b 53 AVERROES 53 multicenter 53 morphometric vertebral fractures 53 double blind placebo 53 Phase III randomized 53 multicentre randomized double 52 secondary endpoints 52 APPRAISE 52 abciximab 52 Ranolazine 52 dose escalation 52 bosentan 52 Randomized 52 everolimus eluting stents 52 Bonferroni 52 eptifibatide 52 GOUT 52 ACCORD Lipid 52 randomized controlled trial 52 tirofiban 52 Phase 2b study 52 univariate 52 Carotid Revascularization Endarterectomy vs. 52 ROCKET AF 52 multicenter randomized controlled 52 TMC# C# 52 pharmacokinetic PK 51 periprocedural MI 51 nonresponders 51 ATACAND 51 secondary endpoint 51 IIIa inhibitor 51 ACCOMPLISH 51 bivalirudin 51 Intervention Effectiveness CATIE 51 Randomized controlled 51 ramipril 51 pharmacodynamic 51 XIENCE V demonstrated 51 CARE HF 51 lacosamide 51 randomized double 51 blinded randomized 51 Non inferiority 51 candesartan 51 multicenter randomized placebo controlled 51 NATRECOR ® 51 phase IIa 51 unblinded 51 regression analyzes 51 multicenter placebo controlled 51 fosbretabulin 51 multivariate analyzes 51 noninferior 51 candesartan cilexetil 51 viral kinetics 51 randomized Phase III 51 observational studies 51 multicenter prospective 51 landmark ATHENA 51 randomized blinded 51 Metabolic Efficiency 51 MIST II 51 irbesartan 51 Sorafenib HCC Assessment 51 PIX# [002] 51 Clinical Antipsychotic Trials 51 HCV RESPOND 2 51 KRN# 51 retrospective cohort 50 SPARCL 50 ARBITER 6 50 placebo controlled Phase III 50 Pharmacokinetic 50 meta analytic 50 lopinavir r 50 Randomized Evaluation 50 ziprasidone 50 Val HeFT 50 RE LY trial 50 cilostazol 50 prospective multicenter randomized 50 TRANSFORMS 50 BOLDER II 50 randomized controlled clinical 50 aripiprazole 50 ADAGIO study 50 Kaplan Meier analysis 50 secondary efficacy endpoints 50 Post hoc 50 IMPROVE IT 50 PFO migraine 50 Intervention Effectiveness 50 phase IIa clinical 50 iloprost 50 plasma pharmacokinetics 50 ezetimibe simvastatin 50 multicenter clinical 50 pegylated interferon alfa 2b 50 secondary efficacy endpoint 50 pharmacokinetic parameters 50 desvenlafaxine succinate 50 VFEND 50 trials BLISS 50 CRESTOR #mg 50 statistically significant 50 valsartan 50 Myocardial Infarction Study 50 multicenter randomized double 50 CHAMPION PLATFORM 50 statistical significance 50 Subgroup analysis 50 telmisartan 50 MEND CABG 50 DSMB 50 eplerenone 50 FOLFIRI 50 prospective observational 50 Phase 2a trial 50 HyQ 50 Phase III VISTA 50 blind randomized placebo 50 citalopram 50 riociguat 50 null hypothesis 50 RLAI 50 LEXIVA r 50 achieve statistical significance 50 randomized controlled clinical trials 50 teriflunomide 50 pairwise comparisons 50 reach statistical significance 50 blind randomized controlled 50 dabigatran etexilate 50 NSABP B 50 SPIRIT III 49 doxorubicin docetaxel 49 oral Xeloda 49 ACUITY trial 49 Phase 2a 49 ILLUMINATE 49 posaconazole 49 Phase 2b trial 49 blinded randomized placebo controlled 49 prospective cohort 49 meta regression 49 ticagrelor 49 randomisation 49 elotuzumab 49 unfractionated heparin UFH 49 PCI ExTRACT TIMI 49 phase IIb clinical 49 Phase IIIb 49 generalizability 49 tolvaptan 49 empiric 49 VADT 49 oral rivaroxaban 49 plus ribavirin 49 efficacy endpoints 49 rosuvastatin 49 tocilizumab 49 rosuvastatin #mg 49 pharmacokinetics PK 49 Meta analyzes 49 bicifadine 49 SABCS 49 nesiritide 49 BRIM3 49 CATIE AD 49 ezetimibe 49 montelukast 49 LOCF 49 BOLDER 49 dose escalation clinical 49 abacavir lamivudine 49 ischemic cardiomyopathy 49 lipid lowering therapy 49 EmbraceAC 49 CAMMS# 49 observational study 49 HeFT 49 prespecified secondary 49 Phase IIb 49 double blinded randomized 49 darunavir ritonavir 49 virologic response 49 ASCEND HF 49 prospective multicentre 49 Initiated Phase 49 prospective randomized placebo 49 mg kg dose 49 prucalopride 49 statistically significant p = 48 correlational 48 TIMI 48 mg BID 48 genotypic resistance 48 masked placebo controlled 48 hypercholesterolemia 48 primary endpoints 48 baseline HbA1c 48 Secondary endpoints 48 ADAS Cog 48 Multicenter 48 PROactive study 48 Randomized trials 48 RIO Lipids 48 BARI 2D 48 factorial 48 NATRECOR R 48 multicenter phase 48 icatibant 48 analgesic efficacy 48 dimebon 48 pharmacokinetic 48 ACTIVE W 48 Bonferroni correction 48 MDRD 48 glatiramer acetate 48 placebo controlled Phase 48 label multicenter 48 MADIT 48 eszopiclone 48 daily Infergen 48 placebo controlled clinical trials 48 prospective nonrandomized 48 ASTEROID 48 recurrent glioblastoma multiforme 48 PERSEUS 48 reboxetine 48 dosing cohorts 48 QLT# 48 NLX P# 48 lipid lowering drugs 48 ECASS 48 paclitaxel eluting stents 48 TAXUS IV 48 Phase Ib clinical 48 mg dose 48 oral diclofenac 48 clinical endpoints 48 PRECISE 48 RE MODEL 48 eprotirome 48 Observational studies 48 Univariate 48 ABC/3TC 48 hemostatic efficacy 48 DURATION 48 AVOREN 48 Phase IIa 48 TDF FTC 48 randomization 48 ADX# 48 AIR CF2 48 randomized multicenter trial 48 NCCTG N# 48 GSK# [001] 48 clinical trial 48 mITT population 48 multicenter study 48 Phase 1b 48 mITT 48 risperidone Risperdal 48 Thrombolysis 48 sirolimus eluting 48 efficacy tolerability 48 #mg QD [002] 48 lamivudine refractory patients 47 echocardiographic 47 Phase IIB 47 metaanalysis 47 glycoprotein IIb IIIa inhibitors 47 nonfatal MI 47 primary efficacy endpoints 47 PREZISTA r 47 boosted protease inhibitor 47 dosage regimens 47 thorough QT 47 nomograms 47 STICH trial 47 dose cohorts 47 covariate 47 CHAMPION PCI 47 placebo controlled multicenter 47 Prospective Randomized Trial 47 ADVANCE PD 47 null responder HCV 47 coadministration 47 MADIT II 47 ACCLAIM 47 ATTRACT 47 abatacept 47 ritonavir boosted 47 REVLIMID lenalidomide 47 phase Ib 47 nonsignificant 47 pharmacokinetic equivalence 47 controlled multicenter 47 AVADO 47 Placebo controlled 47 ADAS cog 47 valproate 47 Phase III placebo controlled 47 Platelet Inhibition 47 myocardial ischemia 47 brivaracetam 47 Multiple Ascending Dose 47 vicriviroc 47 Secondary efficacy endpoints 47 APPROVe 47 #mg dose [003] 47 Phase 1b clinical 47 unfractionated heparin 47 retrospective observational 47 sorafenib Nexavar 47 phase IIb 47 SYMMETRY trial 47 darusentan 47 SPIRIT IV 47 TLUS 47 multicenter Phase II 47 blind placebo controlled 47 blinded placebo controlled 47 HOPE TOO 47 tipranavir 47 Efficacy 47 angiotensin converting enzyme inhibitors 47 HIV RNA 47 TMC# r 47 tolerability 47 multicenter multinational 47 UKPDS 47 clinically meaningful 47 logistic regression analysis 47 CTEPH 47 Polyp Prevention Trial 47 STRIDE PD 47 XELOX 47 efavirenz EFV 47 F FDG PET 47 BENICAR HCT 47 Prostate Cancer Prevention 47 nonparametric 47 HYVET 47 convergent validity 47 MADIT CRT trial 47 interobserver reliability 47 antioxidant supplementation 47 randomized crossover 47 Aggressive Reduction 47 PreCISe study 47 MERIT ES 47 abacavir 47 safety tolerability pharmacokinetics 47 clopidogrel 47 peg interferon 47 Candesartan 47 virologic failure 47 Phase IIa clinical 47 dose escalation Phase 47 methodological flaws 47 multicenter trials 47 label multicenter Phase 47 mg BID dose 47 Phase 2b clinical 47 efficacy endpoint 47 Rating Scale MADRS 47 Solid Tumors 47 EDEMA3 trial 47 REYATAZ r 47 INCB# [003] 47 desvenlafaxine 47 OADs 47 GFT# 47 divalproex 47 antihypertensive agents 47 oxycodone CR 47 Randomized Phase 47 AIR CF1 47 ongoing Phase 1b 47 tanespimycin 47 atrasentan 47 multivariate Cox 47 Fulvestrant 47 aldosterone antagonist 47 QTc 47 infliximab 47 PRECiSE 47 Phase IIa trial 47 tapentadol ER 47 insulin glargine 47 PRIMO CABG2 46 Sibutramine Cardiovascular Outcomes 46 YMRS 46 ConclusionThis 46 ONGLYZA 46 randomized multicentre 46 enoximone 46 PANSS 46 surrogate endpoint 46 PEGINTRON TM 46 Montgomery Asberg Depression 46 evaluable 46 PREVAIL 46 symptomatic VTE 46 Phase 2a clinical 46 Cochrane Systematic Review 46 prospective observational studies 46 dyskinesia PD LID 46 atorvastatin Lipitor 46 rFVIIa 46 APTIVUS r 46 Multivariate logistic regression 46 Controlled Trial 46 FDG PET 46 cisplatin vinorelbine 46 Phase Ib 46 LPV r 46 WHIMS 46 ULORIC 46 EVEREST II 46 Kaplan Meier curves 46 Prostate Lung Colorectal 46 varespladib 46 NPH insulin 46 ENDEAVOR IV 46 amisulpride 46 LVEF 46 cohort 46 subgroup 46 pharmacodynamic effects 46 ivabradine 46 virologic 46 pharmacoeconomic analysis 46 ABCSG 46 pharmacodynamic PD 46 ORAL Sync 46 multicentre study 46 Phase 2b randomized 46 SCD HeFT 46 certolizumab 46 Primary endpoints 46 tipranavir ritonavir 46 Prostate AdenoCarcinoma Treatment 46 Phase 1a clinical 46 attain statistical significance 46 dosing regimens 46 peginterferon 46 Phase IIb III 46 Echocardiographic 46 MMSE score 46 Clinical Outcomes Utilizing Revascularization 46 evaluable subjects 46 dose regimens 46 TEAEs 46 periprocedural 46 sustained virologic response 46 CALGB # [002] 46 Zenvia 46 Pharmacokinetic parameters 46 Acute Ischemic Stroke 46 placebo 46 spontaneous bowel movements 46 efficacy 46 EEG abnormalities 46 serum phosphorous 46 Phase IIIb clinical 46 budesonide 46 cediranib 46 NSTE ACS 46 Adalimumab 46 multiple ascending dose 46 Neuropsychiatric Inventory NPI 46 null responders 46 randomized controlled trials RCTs 46 SYNTAX 46 Phase 2b 46 FOLPI 46 BR.# 46 interobserver 46 XIENCE V PROMUS Stent 46 salmeterol fluticasone 46 Celecoxib APC trial 46 thromboembolic events 46 antipsychotic efficacy 46 tecarfarin 46 CALGB # [001] 46 DAPT 46 confounding variables 46 antihypertensive therapy 46 zolmitriptan 46 Phase IIb clinical 46 neurologic progression 46 Bivalirudin 46 univariate analyzes 46 SCH # 46 DLTs 46 CALGB 46 lispro 46 celgosivir 46 limiting toxicity 46 rosuvastatin Crestor 46 Perforomist Inhalation Solution 46 celecoxib 46 BRIM2 46 logistic regression model 46 pioglitazone 46 rofecoxib 46 bioequivalency 46 MGd 46 mcg dose 46 pharmacodynamics PD 46 ADMIRE HF 46 bezafibrate 46 blind multicenter 46 DEFER 46 eculizumab therapy 46 methodologic 46 pegylated liposomal doxorubicin 46 MoxDuo TM IR 46 Randomized Double blind 46 SVR# 46 mg administered orally 46 Teriflunomide 46 undetectable HBV DNA 46 CANCIDAS 46 Randomized Clinical Trial 46 evaluable patients 46 pivotal bioequivalence 46 avosentan 46 comparator arm 46 multicentre prospective 46 tesmilifene 46 hypertensive patients 46 solifenacin 46 lipid lowering agents 46 unblinding 46 adalimumab 46 statistical significance p 46 Phase 1b trial 46 Unified Parkinson Disease 46 insulin detemir 46 fluvastatin 46 dose escalation phase 46 Edge STudy 46 iniparib 46 ancrod 46 BCIRG 46 ascending dose 46 paricalcitol 45 Tolvaptan 45 dose escalation study 45 Traficet EN 45 nonrandomized studies 45 asymptomatic metastatic 45 GISSI HF 45 conditional logistic regression 45 mg doses 45 statistically significant superiority 45 monotherapy 45 CRx 45 lumbar spine BMD 45 HORIZONS AMI trial 45 randomizing patients 45 mg QD 45 retrospective cohort study 45 IMPROVE HF 45 NCT# ClinicalTrials.gov 45 epidemiologic studies 45 mg/m2 dose 45 PACCE trial 45 subclinical cardiovascular disease 45 NRTI 45 definite stent thrombosis 45 NNRTI resistance 45 multicenter randomized clinical 45 metastatic castration resistant 45 ruboxistaurin 45 aliskiren 45 retrospective observational study 45 mcg kg 45 Welchol 45 standard chemotherapy regimen 45 SORT OUT III 45 Navelbine 45 generation antipsychotics 45 peg IFN 45 certolizumab pegol 45 LEVADEX 45 Aggressive Drug Evaluation 45 antiarrhythmic drug 45 dose escalation trial 45 discontinuations 45 Response Evaluation Criteria 45 Relieve Depression 45 CYPHER Stent 45 blinded randomized controlled 45 azacitidine 45 IMPACT DCM 45 immunohistochemical 45 chest radiographs 45 tigecycline 45 mGluR5 NAM 45 Dacogen injection 45 paliperidone ER 45 Pharmacokinetic studies 45 clazosentan 45 NEVO RES 45 plus dexamethasone 45 pramipexole 45 divalproex sodium 45 CONSORT 45 d4T 45 Intervention Trial 45 Acute Myocardial Infarction 45 ACTEMRA TM 45 COMFORT II 45 pregabalin 45 serotonin norepinephrine reuptake inhibitor 45 unmeasured confounders 45 Ceplene/IL-2 45 PRE SURGE 45 statin therapy 45 Androxal TM 45 randomized multicenter Phase III 45 sirolimus eluting stents 45 metastatic HRPC 45 placebo controlled dose escalation 45 clevidipine 45 allopurinol 45 pharmacokinetic PK study 45 Dose escalation 45 evaluating tivozanib 45 antidepressant efficacy 45 Aptivus ® 45 CAVEATS 45 alteplase 45 left ventricular dysfunction 45 premorbid 45 fluoxetine 45 tiotropium 45 postintervention 45 CR nPR 45 atorvastatin #mg 45 teriparatide 45 diuretic chlorthalidone 45 oxcarbazepine 45 antitumor effect 45 adjuvant chemotherapy 45 REALITY Trial 45 FDA defined valvulopathy 45 NO# [002] 45 Ereska 45 sirolimus eluting stent 45 APEX AMI trial 45 acamprosate 45 #mg BID [002] 45 CLL8 45 Logistic regression 45 sorafenib 45 Phase Ib study 45 sitagliptin 45 methodological limitations 45 Randomized Double Blind Placebo 45 RECIST Response Evaluation Criteria 45 donepezil 45 interferon gamma 1b 45 Trandolapril 45 nicardipine 45 NIHSS score 45 LV dysfunction 45 LUX Lung 45 armodafinil 45 β blockers 45 safinamide 45 bivariate analyzes 45 levosimendan 45 NYHA functional class 45 CYPHER ® Stent 45 Abciximab 45 AEGR 45 randomized Phase IIb 45 Prospective Multicenter 45 confirmatory Phase III 45 Double Blind Randomized 45 Tiotropium 45 alvimopan 45 Left Ventricular Dysfunction 45 IMPACT IMmunotherapy 45 heartwire 45 NEVO ™ 45 Intervention Trial GAIT 45 dose proportionality 45 pertuzumab 45 histopathological 45 macrovascular 45 HAM D# 45 ertapenem 45 ROZEREM TM 45 Montgomery Åsberg Depression 45 phase IIb trial 45 diabetic neuropathic pain 45 ADHF 45 Phase III 45 ZOLINZA 45 PARTNER Trial 45 serum creatinine levels 45 exploratory endpoints 45 PRIMO CABG 45 EMPHASIS HF 45 HF ACTION 45 Phase 1a 45 chlorthalidone 45 ACE inhibitor ramipril 45 Xelox 45 PCPT 45 Trial ASCOT 45 residual confounding 45 randomized controlled multicenter 45 alvespimycin 45 aminotransferase levels 45 SYNTAX trial 45 carboplatin paclitaxel 45 Percutaneous Coronary Intervention 45 ADHD RS 45 prazosin 45 ILLUSTRATE 45 n = 45 randomized controlled Phase 45 aspirin clopidogrel 45 tasocitinib 45 recurrent GBM 45 liver histology 45 nonclinical studies 45 MOTIVATE 45 pomalidomide 45 familial aggregation 45 EDEMA3 45 EINSTEIN DVT 45 carotid IMT 45 multicenter Phase III 45 factorial design 45 demonstrated statistically significant 45 CIMZIA TM certolizumab pegol 45 rivaroxaban 45 locoregional recurrence 45 confounder 45 recurrent ischemia 45 Primary Endpoint 45 temsirolimus 44 angiographic outcomes 44 everolimus eluting stent 44 NHANES III 44 sUA 44 μg kg 44 TG MV 44 fosamprenavir 44 dose statin therapy 44 neratinib 44 EBUS FNA 44 EchoCRT 44 serum uric acid 44 dalteparin 44 DMARD 44 Endpoints 44 FOSRENOL ® 44 double blinded placebo 44 rotigotine 44 PRoFESS 44 tricyclic antidepressants 44 statistically significant p 44 inferential statistics 44 designated HVTN 44 antiplatelet agent 44 nausea photophobia 44 Phase IIb trial 44 Monitoring ABPM 44 chemotherapy docetaxel 44 tipranavir r 44 creatinine clearance 44 NEVO 44 conventional coronary angiography 44 RECORD1 44 coronary revascularization 44 HDRS 44 etanercept 44 alpha 2a 44 tamsulosin 44 binary restenosis 44 CAPRIE 44 Phase #/#a 44 #mg BID [001] 44 ocrelizumab 44 zonisamide SR 44 covariance ANCOVA 44 NIHSS 44 quetiapine 44 Stenting Trial CREST 44 eGFR 44 CALERIE 44 CIMZIA TM 44 nondiabetic patients 44 II Clinical Trial 44 Kaplan Meier survival 44 goserelin 44 Pegasys ® 44 nonoperative treatment 44 mycophenolate mofetil 44 Phase Ib II 44 Alzheimer Disease Assessment 44 ximelagatran 44 Randomized Phase II 44 PREVENT IV 44 dextromethorphan quinidine 44 Proellex TM 44 AFFIRM 44 Doxil ® 44 phase Ib clinical 44 elective PCI 44 intravenous dosing 44 trastuzumab emtansine T DM1 44 stone formers 44 Blind Placebo Controlled Trial 44 ketorolac 44 urinary N telopeptide 44 mcg BID 44 #.#/#.# mmHg [001] 44 demonstrated clinically meaningful 44 virus HCV protease inhibitor 44 mg RDEA# 44 nephron sparing surgery 44 multiple logistic regression 44 MADRS 44 thromboembolic 44 lubiprostone 44 UPDRS 44 Zenvia ™ 44 rt PA 44 bivariate 44 prospectively 44 International Verapamil SR 44 mildly symptomatic 44 causal inference 44 R# #mg BID 44 intraobserver 44 neoadjuvant chemotherapy 44 FOLFOX4 44 #:# randomization 44 Observational Study 44 atherothrombotic disease 44 TAXUS Stent 44 dosing cohort 44 Parkinson disease levodopa induced 44 mapatumumab 44 registrational Phase 44 dichotomized 44 peginterferon alfa 2a 44 lintuzumab 44 Raloxifene Evaluation MORE 44 melphalan prednisone 44 Brief Psychiatric 44 multinational multicenter randomized 44 dose dose escalation 44 lamotrigine 44 Glucosamine Chondroitin Arthritis 44 QD dosing 44 inhibitor RG# 44 dabigatran 44 acute mania 44 statistically nonsignificant 44 clinical pharmacology studies 44 confirmatory clinical 44 phase 2a 44 tolerability pharmacokinetics 44 atazanavir 44 TAXUS ATLAS 44 Sequenced Treatment Alternatives 44 risedronate 44 fasting glucose levels 44 Antihypertensive 44 logistic regression 44 prospectively randomized 44 comorbidity 44 enzastaurin 44 posttreatment 44 plus COPEGUS 44 clinically meaningful differences 44 Multivariate analysis 44 SEROQUEL 44 5-FU/LV 44 Taxotere ® 44 radical cystectomy 44 NICE SUGAR 44 relapsed MM 44 Phase III clinical 44 headache nasopharyngitis 44 abacavir Ziagen 44 extrapyramidal symptoms 44 logistic regression models 44 Kruskal Wallis test 44 QTc prolongation 44 label dose titration 44 Betaferon ® 44 CIMZIA ™ 44 Phase III multicenter 44 PEG IFN 44 rolofylline 44 neoadjuvant 44 HbA1c levels 44 registrational 44 Communities ARIC study 44 Phase III randomized controlled 44 Lipid Lowering Treatment 44 Placebo Controlled Trial 44 selenium supplementation 44 Scandinavian Cardiac Outcomes 44 KRAS mutation 44 nonpsychotic 44 NEJM 44 salmeterol 44 NSABP C 44 HMG CoA reductase inhibitors 44 CLBP 44 dose clopidogrel 44 EORTC 44 FAME Study 44 #mg/day [001] 44 SIMPADICO 44 Randomized Controlled 44 Board DSMB 44 neostigmine 44 apremilast 44 invasive aspergillosis 44 Valsartan 44 ritonavir boosted atazanavir 44 BoNTA 44 NIH CPSI 44 Val MARC 44 #mg BID [003] 44 alicaforsen enema 44 TNF inhibitor